GSK (GSK): news on Thursday 8 October 2026

The 16 stories

Each headline's own score, strongest first. Links go to the publisher.

• +8.3 GSK plc : Berenberg remains its Buy rating www.marketscreener.com
  Berenberg maintains its Buy rating.
• +8.3 Berenberg keeps Buy rating and GBp 2,200 target for GSK stock AD HOC NEWS
  Berenberg keeps Buy rating with a 2,200p target.
• +7.5 GSK: The Gas Pedal Is Finally Down (NYSE:GSK) Seeking Alpha
  Analyst commentary positive on strategy acceleration.
• +7.5 Why Has FTSE 100 GSK (LSE:GSK) Taken Global Rights to a Chimagen Myeloma Drug? Kalkine Media
  Takes global rights to a Chimagen myeloma drug.
• +6.7 GSK (LSE:GSK) Adds A New Hepatology Candidate, Is The 18% Undervaluation Case Intact? Simply Wall Street
  New hepatology candidate; shares seen as undervalued.
• +6.7 GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships Yahoo Finance
  Two research partnerships deepen the drug pipeline.
• +6.7 GSK accelerates transformation with M&A and pip... Pluang
  Transformation via M&A and pipeline additions framed positively.
• +6.7 GSK’s Tuas vaccine facility is Singapore’s largest after S$300 million investment: Gan Kim Yong Singapore Economic Development Board (EDB)
  Large Singapore vaccine facility after S$300 million investment.
• +6.7 GSK stock adds a liver candidate to its pipeline AD HOC NEWS
  Adds a liver candidate to its pipeline.
• +4.2 Can HUTCHMED (LSE:HCM) turn its FTSE 100 partner GSK into clinical momentum after dosing a first patient? Kalkine Media
  Partner HUTCHMED dosed first patient in GSK-linked programme.
• +4.2 GSK (LSE:GSK) Stock May Trade Below Fair Value Despite Fresh Cabenuva Trial News Yahoo Finance
  Fresh Cabenuva trial news; possibly trading below fair value.
• +3.3 GSK’s ViiV Healthcare reports CROWN endpoint: GSK stock pre-market at EUR 20.86, minus 0.62 percen AD HOC NEWS
  ViiV trial endpoint reported; share price slightly lower pre-market.
• +2.5 AI-Powered Demand Forecasting: GSK's Digital Transformation Journey C3 AI
  Case study on its digital demand forecasting; mildly positive.
• +2.5 Former Sensodyne boss behind launch of new toothpaste for sensitive teeth Exmouth Journal
  New toothpaste launch tied to a former Sensodyne boss; minor.
• +1.7 Momentum Weakens, GSK Stock Gains 1.42%: What to Know JournalArta
  Shares gained 1.42% though momentum is weakening.
• −1.7 GSK shares technical analysis: Resistance test at GBX1,769 limits rebound Traders Union
  Technical resistance limits the share price rebound.